Suprane (desflurane) NDC 0404-9961

NDC codes

FDA NDC Directory

Product NDC (as listed)0404-9961Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00404-9961Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0404-9961-25	00404996125	1 BOTTLE in 1 BAG (0404-9961-25) / 240 mL in 1 BOTTLEMarketed from Jan 12, 2022

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Suprane
Generic name (nonproprietary): desflurane
Active ingredients: Desflurane — 240 mL/240mL
Dosage form: Liquid
Route: Respiratory (Inhalation)
Labeler: Henry Schein, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020118
Marketing start: Jan 12, 2022
Listing expires: Dec 31, 2027
Other FDA classes: General Anesthesia (Physiologic effect)
Identifiers: Product ID 0404-9961_55ccfa99-0261-4ca1-9f31-1d934c825a8bSPL ID 55ccfa99-0261-4ca1-9f31-1d934c825a8bSPL set ID a3e4c8e5-bff0-4a8f-8401-e9866c846ee2RxCUI 208919, 562366UNII CRS35BZ94Q
Pharmacologic class: General Anesthetic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N400404996125 followed by a unit qualifier and the quantity

Package 00404-9961-25. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 15, 2026.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE 1.1 Induction of Anesthesia SUPRANE is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. SUPRANE is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. 1.2 Maintenance of Anesthesia SUPRANE is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. After induction of anesthesia with agents other than SUPRANE, and tracheal intubation, SUPRANE is indicated for maintenance of anesthesia in infants and children. SUP…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)